12th Annual Meeting of the Society of Urologic Oncology (SUO) Bladder Cancer Sessions I and II summary report

Sam S. Chang, Colin P N Dinney, S. Machele Donat, Philipp Dahm, John L. Gore, Yair Lotan, Dipen J. Parekh, David B. Solit, Peter H. O'Donnell, Felix Y. Feng, Donna Hansel, Matthew I. Milowsky

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Health care reform with the Affordable Care Act aims to control health care costs, in part, through the use of comparative effectiveness research and quality of care measures. Bladder cancer is one of the most expensive malignancies to manage as related to the need for continuous monitoring and the treatment of recurrence. The use of clinical practice guidelines relying on evidence based medicine in the management of patients with bladder cancer will help to ensure quality of care and cost containment. The goal of session I was to provide a thorough discussion of the quality of care and cost issues related to bladder cancer including an examination of levels of evidence, implementation and compliance with clinical practice guidelines, the use of standardized reporting methodologies, and comparative effectiveness research. Bladder cancer is a common malignancy with a variable biology and natural history. Although the majority of patients are diagnosed with non-invasive disease, approximately 20-40% of patients either present with or develop more advanced disease. The 5-year survival for patients with lymph node involvement at the time of surgery is 20-30% and patients with metastatic disease treated with chemotherapy have a median survival of only 15 months. Novel approaches for the management of patients with bladder cancer are desperately needed. The goal of session II was to review the current state of translational research in bladder cancer as related to both early and late stage disease including a discussion of novel molecular targets and targeted therapeutics, pharmacogenomics to predict response to therapy, and exploring the role for agents targeting angiogenesis.

Original languageEnglish (US)
Pages (from-to)944-947
Number of pages4
JournalUrologic Oncology: Seminars and Original Investigations
Volume30
Issue number6
DOIs
StatePublished - Nov 2012

Fingerprint

Urinary Bladder Neoplasms
Quality of Health Care
Comparative Effectiveness Research
Practice Guidelines
Patient Protection and Affordable Care Act
Translational Medical Research
Health Care Reform
Survival
Cost Control
Evidence-Based Medicine
Pharmacogenetics
Natural History
Health Care Costs
Neoplasms
Therapeutics
Lymph Nodes
Costs and Cost Analysis
Recurrence
Drug Therapy

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

12th Annual Meeting of the Society of Urologic Oncology (SUO) Bladder Cancer Sessions I and II summary report. / Chang, Sam S.; Dinney, Colin P N; Donat, S. Machele; Dahm, Philipp; Gore, John L.; Lotan, Yair; Parekh, Dipen J.; Solit, David B.; O'Donnell, Peter H.; Feng, Felix Y.; Hansel, Donna; Milowsky, Matthew I.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 30, No. 6, 11.2012, p. 944-947.

Research output: Contribution to journalArticle

Chang, SS, Dinney, CPN, Donat, SM, Dahm, P, Gore, JL, Lotan, Y, Parekh, DJ, Solit, DB, O'Donnell, PH, Feng, FY, Hansel, D & Milowsky, MI 2012, '12th Annual Meeting of the Society of Urologic Oncology (SUO) Bladder Cancer Sessions I and II summary report', Urologic Oncology: Seminars and Original Investigations, vol. 30, no. 6, pp. 944-947. https://doi.org/10.1016/j.urolonc.2012.07.006
Chang, Sam S. ; Dinney, Colin P N ; Donat, S. Machele ; Dahm, Philipp ; Gore, John L. ; Lotan, Yair ; Parekh, Dipen J. ; Solit, David B. ; O'Donnell, Peter H. ; Feng, Felix Y. ; Hansel, Donna ; Milowsky, Matthew I. / 12th Annual Meeting of the Society of Urologic Oncology (SUO) Bladder Cancer Sessions I and II summary report. In: Urologic Oncology: Seminars and Original Investigations. 2012 ; Vol. 30, No. 6. pp. 944-947.
@article{113887efd3f34b408dd55049755304b2,
title = "12th Annual Meeting of the Society of Urologic Oncology (SUO) Bladder Cancer Sessions I and II summary report",
abstract = "Health care reform with the Affordable Care Act aims to control health care costs, in part, through the use of comparative effectiveness research and quality of care measures. Bladder cancer is one of the most expensive malignancies to manage as related to the need for continuous monitoring and the treatment of recurrence. The use of clinical practice guidelines relying on evidence based medicine in the management of patients with bladder cancer will help to ensure quality of care and cost containment. The goal of session I was to provide a thorough discussion of the quality of care and cost issues related to bladder cancer including an examination of levels of evidence, implementation and compliance with clinical practice guidelines, the use of standardized reporting methodologies, and comparative effectiveness research. Bladder cancer is a common malignancy with a variable biology and natural history. Although the majority of patients are diagnosed with non-invasive disease, approximately 20-40{\%} of patients either present with or develop more advanced disease. The 5-year survival for patients with lymph node involvement at the time of surgery is 20-30{\%} and patients with metastatic disease treated with chemotherapy have a median survival of only 15 months. Novel approaches for the management of patients with bladder cancer are desperately needed. The goal of session II was to review the current state of translational research in bladder cancer as related to both early and late stage disease including a discussion of novel molecular targets and targeted therapeutics, pharmacogenomics to predict response to therapy, and exploring the role for agents targeting angiogenesis.",
author = "Chang, {Sam S.} and Dinney, {Colin P N} and Donat, {S. Machele} and Philipp Dahm and Gore, {John L.} and Yair Lotan and Parekh, {Dipen J.} and Solit, {David B.} and O'Donnell, {Peter H.} and Feng, {Felix Y.} and Donna Hansel and Milowsky, {Matthew I.}",
year = "2012",
month = "11",
doi = "10.1016/j.urolonc.2012.07.006",
language = "English (US)",
volume = "30",
pages = "944--947",
journal = "Urologic Oncology: Seminars and Original Investigations",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - 12th Annual Meeting of the Society of Urologic Oncology (SUO) Bladder Cancer Sessions I and II summary report

AU - Chang, Sam S.

AU - Dinney, Colin P N

AU - Donat, S. Machele

AU - Dahm, Philipp

AU - Gore, John L.

AU - Lotan, Yair

AU - Parekh, Dipen J.

AU - Solit, David B.

AU - O'Donnell, Peter H.

AU - Feng, Felix Y.

AU - Hansel, Donna

AU - Milowsky, Matthew I.

PY - 2012/11

Y1 - 2012/11

N2 - Health care reform with the Affordable Care Act aims to control health care costs, in part, through the use of comparative effectiveness research and quality of care measures. Bladder cancer is one of the most expensive malignancies to manage as related to the need for continuous monitoring and the treatment of recurrence. The use of clinical practice guidelines relying on evidence based medicine in the management of patients with bladder cancer will help to ensure quality of care and cost containment. The goal of session I was to provide a thorough discussion of the quality of care and cost issues related to bladder cancer including an examination of levels of evidence, implementation and compliance with clinical practice guidelines, the use of standardized reporting methodologies, and comparative effectiveness research. Bladder cancer is a common malignancy with a variable biology and natural history. Although the majority of patients are diagnosed with non-invasive disease, approximately 20-40% of patients either present with or develop more advanced disease. The 5-year survival for patients with lymph node involvement at the time of surgery is 20-30% and patients with metastatic disease treated with chemotherapy have a median survival of only 15 months. Novel approaches for the management of patients with bladder cancer are desperately needed. The goal of session II was to review the current state of translational research in bladder cancer as related to both early and late stage disease including a discussion of novel molecular targets and targeted therapeutics, pharmacogenomics to predict response to therapy, and exploring the role for agents targeting angiogenesis.

AB - Health care reform with the Affordable Care Act aims to control health care costs, in part, through the use of comparative effectiveness research and quality of care measures. Bladder cancer is one of the most expensive malignancies to manage as related to the need for continuous monitoring and the treatment of recurrence. The use of clinical practice guidelines relying on evidence based medicine in the management of patients with bladder cancer will help to ensure quality of care and cost containment. The goal of session I was to provide a thorough discussion of the quality of care and cost issues related to bladder cancer including an examination of levels of evidence, implementation and compliance with clinical practice guidelines, the use of standardized reporting methodologies, and comparative effectiveness research. Bladder cancer is a common malignancy with a variable biology and natural history. Although the majority of patients are diagnosed with non-invasive disease, approximately 20-40% of patients either present with or develop more advanced disease. The 5-year survival for patients with lymph node involvement at the time of surgery is 20-30% and patients with metastatic disease treated with chemotherapy have a median survival of only 15 months. Novel approaches for the management of patients with bladder cancer are desperately needed. The goal of session II was to review the current state of translational research in bladder cancer as related to both early and late stage disease including a discussion of novel molecular targets and targeted therapeutics, pharmacogenomics to predict response to therapy, and exploring the role for agents targeting angiogenesis.

UR - http://www.scopus.com/inward/record.url?scp=84870482810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870482810&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2012.07.006

DO - 10.1016/j.urolonc.2012.07.006

M3 - Article

VL - 30

SP - 944

EP - 947

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

SN - 1078-1439

IS - 6

ER -